Shares of Circio Holding ASA surged as much as 29.8% to NOK 11.92 after the tiny Norwegian biotech's extraordinary general meeting on August 25 approved two new board members and renewed the company's authority to issue new shares — a routine-sounding corporate event that triggered an outsized market reaction. Circio Adds Gene-Therapy Heavyweight to Its Board and Shares Jump 30% — Can a 10-Person Preclinical Biotech Sustain a NOK 2 Billion Valuation?
Shares of Oslo-listed Circio Holding ASA rocketed 29.8% to NOK 11.92 after its August 25 extraordinary general meeting rubber-stamped two board appointments and renewed the company's authority to sell new shares. The move caps a year of extraordinary transformation for a 10-employee company with essentially zero revenue that has reshaped itself from a struggling cancer-vaccine firm into a circular RNA gene-therapy platform play.
A Star Hire Signals Circio Is Serious About the Clinic. Dr. Dinah Sah, an RNA and gene-therapy expert with experience as chief scientific officer of Voyager Therapeutics and VP of research at Alnylam Pharmaceuticals, is expected to bolster the board's scientific expertise as Circio advances a lead gene-therapy candidate toward clinical entry.
Dr. Robert Burns, who has served on Circio's board for over 15 years, was also elevated from deputy director, ensuring continuity. For a micro-cap company targeting a first-in-human trial in 2029, Sah's pedigree is the kind of credential that helps attract pharma partners — and more investor capital.
NOK 620 Million Raised This Year Buys Time, but Dilution Is Real. Circio completed a NOK 300 million financing round in June, extending its cash runway to the end of 2030 and bringing total capital raised in the first half of 2026 to approximately NOK 620 million (€57 million).
The company has just 10 employees. That funding cushion is unusual for a preclinical-stage firm, but it came at a cost: massive share issuance that ballooned the count to roughly 274 million shares. The renewed capital-increase authorization means further dilution — selling new shares to raise cash — remains on the table.
Preclinical Data Is Promising but Years from Payoff. New in vivo data demonstrate up to 50-fold enhanced gene expression in the eye and validated 40-fold enhancement in the heart, with 80% of heart cells showing expression after systemic delivery. Those are striking lab-stage results, but no drug candidate has entered human trials. Circio's stock has been one of the more volatile biotech stories on the Oslo market this year, with Norwegian press noting a 2,500% run-up over the prior year followed by a steep correction.
The Bottom Line. Circio's market cap sits at roughly NOK 2.2 billion, having increased over 3,400% in one year. Investors are betting that the circular RNA platform and fresh board talent can bridge the gap between compelling preclinical science and a real drug. With earnings due August 31, the next test comes in days.